Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06648824
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Allyx Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT06632990
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Remimazolam Versus Midazolam for Sedation During Upper GI Endoscopy: a Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Koen Munters
- Target Recruit Count
- 148
- Registration Number
- NCT06614036
- Locations
- 🇳🇱
Gelre Hospitals, Apeldoorn, Gelderland, Netherlands
🇳🇱Rijnstate hospital, Arnhem, Gelderland, Netherlands
🇳🇱St Antonius hospital, Nieuwegein, Utrecht, Netherlands
A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06575933
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT06564441
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- TenNor Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06551623
- Locations
- 🇨🇳
The First Hospital of Jinlin University, Changchun, Jilin, China
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06547164
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 48
- Registration Number
- NCT06503679
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06494761
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT06417125
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.